Akari Therapeutics to Present at the 2026 Biotech Showcase
Rhea-AI Summary
Akari Therapeutics (Nasdaq: AKTX) will present in person at the 2026 Biotech Showcase in San Francisco on Tuesday, January 13, 2026 at 9:30 AM PST in Yosemite A (Ballroom Level).
Abizer Gaslightwala, President and CEO, will overview Akari’s ADC platform, strategic priorities and key milestones for 2026. Management will also be available for in-person one-on-one meetings with registered, qualified investors during the conference running January 12–14, 2026.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, AKTX declined 1.74%, reflecting a mild negative market reaction. This price movement removed approximately $246K from the company's valuation, bringing the market cap to $14M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AKTX slipped -0.9% while peers showed mixed moves: QTTB -2.92%, RNTX +0.82%, KZR +0.80%, LIXT +5.07%, ALLR +4.50%. With no peers in the momentum scanner and no same-day peer news, the setup looks stock-specific rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 30 | Year-end update | Positive | +2.3% | Letter outlining 2025 ADC progress and 2026–2027 clinical plans. |
| Dec 23 | Manufacturing milestone | Positive | -7.1% | Start of GMP manufacturing for AKTX-101 with WuXi XDC. |
| Dec 18 | Investor outreach | Positive | -2.2% | Virtual investor segment explaining PH1 payload and AKTX-101 plans. |
| Dec 16 | Equity financing | Negative | -38.3% | Approx. $5M direct offering and private placement with warrants. |
| Dec 09 | Preclinical data | Positive | +3.2% | AKTX-101 preclinical efficacy data in K-Ras mutant PDAC models. |
Recent news shows mixed alignment: positive R&D updates sometimes met with selling, while financing and strong preclinical data drew sharper price moves.
Over the past months, Akari has focused on advancing its ADC platform and lead candidate AKTX-101, highlighting preclinical data, manufacturing progress, and long-range plans for a Phase 1 trial around late 2026/2027. Financing in mid-December 2025 brought significant dilution and a sharp negative reaction, while later preclinical and corporate updates produced smaller, mixed price moves. Today’s conference presentation fits the pattern of ongoing investor outreach following these R&D and financing milestones.
Regulatory & Risk Context
The company has an active S-3 shelf registration dated 2025-07-29, with reported usage via at least 2 prospectus supplements, indicating an established mechanism for potential future capital raises.
Market Pulse Summary
This announcement highlights Akari’s participation in the 2026 Biotech Showcase, where management plans to present its ADC platform, 2026 strategic priorities, and milestones and to hold one-on-one investor meetings. It continues a sequence of investor-focused communications following preclinical updates and recent financings. Investors may watch for any new details on timelines for the planned Phase 1 trial of AKTX-101, funding plans, and how the company frames its competitive positioning in ADCs.
Key Terms
antibody drug conjugates medical
adc platform medical
AI-generated analysis. Not financial advice.
In-person presentation on Tuesday, January 13th at 9:30 AM PT
As part of the presentation, Mr. Gaslightwala will provide an overview of Akari’s ADC platform, strategic priorities and key milestones for 2026
TAMPA, Fla. and LONDON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics will present at the 2026 Biotech Showcase being held from January 12-14, 2026 in San Francisco, CA.
Presentation details are as follows:
Date/Time: Tuesday, January 13, 2026 at 9:30 AM PST
Location: Yosemite A (Ballroom Level)
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune system to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGF3, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by late 2026/early 2027, and is also advancing AKTX-102, an ADC against a novel target highly relevant in GI and lung cancers.
For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com
FAQ
When and where will Akari Therapeutics (AKTX) present at the 2026 Biotech Showcase?
Who from Akari Therapeutics (AKTX) will present at the January 2026 conference?
What topics will Akari (AKTX) cover in the Biotech Showcase presentation?
Can investors meet with Akari Therapeutics (AKTX) management at the Biotech Showcase?
How long does the 2026 Biotech Showcase take place and when should attendees register?
